Digging into biomarkers of immunologic transplant rejection
William Aryitey |
“There is a critical need for time-sensitive, noninvasive biomarkers to monitor transplant organ rejection or injury,” says Prashanth Vallabhajosyula, assistant professor of surgery at the Hospital of the University of Pennsylvania. “In transplant patients, complications associated with transplant organ rejection/injury, and with the required immunosuppressive drugs, are the major causes of morbidity and mortality. Therefore, any biomarker platform that can accurately enable noninvasive monitoring of the transplanted organ would have a direct translational impact.” To that end, Vallabhajosyula and a team of researchers (also from the University of Pennsylvania) showed that blood-based transplant exosomes can be a noninvasive alternative to needle biopsy in islet and renal transplants (1).
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.